Literature DB >> 19208743

Yin yang 1 modulates taxane response in epithelial ovarian cancer.

Noriomi Matsumura1, Zhiqing Huang, Tsukasa Baba, Paula S Lee, Jason C Barnett, Seiichi Mori, Jeffrey T Chang, Wen-Lin Kuo, Alison H Gusberg, Regina S Whitaker, Joe W Gray, Shingo Fujii, Andrew Berchuck, Susan K Murphy.   

Abstract

Survival of ovarian cancer patients is largely dictated by their response to chemotherapy, which depends on underlying molecular features of the malignancy. We previously identified YIN YANG 1 (YY1) as a gene whose expression is positively correlated with ovarian cancer survival. Herein, we investigated the mechanistic basis of this association. Epigenetic and genetic characteristics of YY1 in serous epithelial ovarian cancer were analyzed along with YY1 mRNA and protein. Patterns of gene expression in primary serous epithelial ovarian cancer and in the NCI60 database were investigated using computational methods. YY1 function and modulation of chemotherapeutic response in vitro was studied using small interfering RNA knockdown. Microarray analysis showed strong positive correlation between expression of YY1 and genes with YY1 and transcription factor E2F binding motifs in ovarian cancer and in the NCI60 cancer cell lines. Clustering of microarray data for these genes revealed that high YY1/E2F3 activity positively correlates with survival of patients treated with the microtubule-stabilizing drug paclitaxel. Increased sensitivity to taxanes, but not to DNA cross-linking platinum agents, was also characteristic of NCI60 cancer cell lines with a high YY1/E2F signature. YY1 knockdown in ovarian cancer cell lines results in inhibition of anchorage-independent growth, motility, and proliferation but also increases resistance to taxanes, with no effect on cisplatin sensitivity. These results, together with the prior demonstration of augmentation of microtubule-related genes by E2F3, suggest that enhanced taxane sensitivity in tumors with high YY1/E2F activity may be mediated by modulation of putative target genes with microtubule function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208743      PMCID: PMC2675878          DOI: 10.1158/1541-7786.MCR-08-0255

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  37 in total

1.  GATHER: a systems approach to interpreting genomic signatures.

Authors:  Jeffrey T Chang; Joseph R Nevins
Journal:  Bioinformatics       Date:  2006-09-25       Impact factor: 6.937

2.  Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma.

Authors:  C A Bandera; H Takahashi; K Behbakht; P C Liu; V A LiVolsi; I Benjamin; M A Morgan; S A King; S C Rubin; J Boyd
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

3.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

Authors:  Andrea H Bild; Guang Yao; Jeffrey T Chang; Quanli Wang; Anil Potti; Dawn Chasse; Mary-Beth Joshi; David Harpole; Johnathan M Lancaster; Andrew Berchuck; John A Olson; Jeffrey R Marks; Holly K Dressman; Mike West; Joseph R Nevins
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

Review 4.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology.

Authors:  S Gordon; G Akopyan; H Garban; B Bonavida
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

Review 5.  Understanding microtubule dynamics for improved cancer therapy.

Authors:  S Honore; E Pasquier; D Braguer
Journal:  Cell Mol Life Sci       Date:  2005-12       Impact factor: 9.261

6.  E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents.

Authors:  Angelo J Russo; Pellegrino G Magro; Zhen Hu; Wei-Wei Li; Rowayda Peters; Jennifer Mandola; Debabrata Banerjee; Joseph R Bertino
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

7.  Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression.

Authors:  El Bachir Affar; Frédérique Gay; Yujiang Shi; Huifei Liu; Maite Huarte; Su Wu; Tucker Collins; En Li; Yang Shi
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

8.  Characterization of FIII/YY1, a Xenopus laevis conserved zinc-finger protein binding to the first exon of L1 and L14 ribosomal protein genes.

Authors:  G Pisaneschi; S Ceccotti; M L Falchetti; S Fiumicino; F Carnevali; E Beccari
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

Review 9.  Multifunctional transcription factor YY1: a therapeutic target in human cancer?

Authors:  Chi-Chung Wang; Jeremy J W Chen; Pan-Chyr Yang
Journal:  Expert Opin Ther Targets       Date:  2006-04       Impact factor: 6.902

10.  The Drosophila Polycomb group gene pleiohomeotic encodes a DNA binding protein with homology to the transcription factor YY1.

Authors:  J L Brown; D Mucci; M Whiteley; M L Dirksen; J A Kassis
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

View more
  25 in total

1.  LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.

Authors:  Jennifer Permuth-Wey; Donghwa Kim; Ya-Yu Tsai; Hui-Yi Lin; Y Ann Chen; Jill Barnholtz-Sloan; Michael J Birrer; Gregory Bloom; Stephen J Chanock; Zhihua Chen; Daniel W Cramer; Julie M Cunningham; Getachew Dagne; Judith Ebbert-Syfrett; David Fenstermacher; Brooke L Fridley; Montserrat Garcia-Closas; Simon A Gayther; William Ge; Aleksandra Gentry-Maharaj; Jesus Gonzalez-Bosquet; Ellen L Goode; Edwin Iversen; Heather Jim; William Kong; John McLaughlin; Usha Menon; Alvaro N A Monteiro; Steven A Narod; Paul D P Pharoah; Catherine M Phelan; Xiaotao Qu; Susan J Ramus; Harvey Risch; Joellen M Schildkraut; Honglin Song; Heather Stockwell; Rebecca Sutphen; Kathryn L Terry; Jonathan Tyrer; Robert A Vierkant; Nicolas Wentzensen; Johnathan M Lancaster; Jin Q Cheng; Thomas A Sellers
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

Review 2.  Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects.

Authors:  Michael Atchison; Arindam Basu; Kristina Zaprazna; Madhusudhan Papasani
Journal:  Crit Rev Oncog       Date:  2011

Review 3.  The oncogenic role of Yin Yang 1.

Authors:  Qiang Zhang; Daniel B Stovall; Kazushi Inoue; Guangchao Sui
Journal:  Crit Rev Oncog       Date:  2011

4.  Transcription regulator Yin-yang 1: from silence to cancer.

Authors:  Weidong Zhu; Samuel Y Olson; Hermes Garbán
Journal:  Crit Rev Oncog       Date:  2011

5.  Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha.

Authors:  Shengjie Zhang; Tingting Jiang; Lifeng Feng; Jie Sun; Haiqi Lu; Qinchuan Wang; Min Pan; Dongsheng Huang; Xian Wang; Linbo Wang; Hongchuan Jin
Journal:  J Mol Med (Berl)       Date:  2012-03-06       Impact factor: 4.599

Review 6.  Neomorphic mutations create therapeutic challenges in cancer.

Authors:  V Takiar; C K M Ip; M Gao; G B Mills; L W T Cheung
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

7.  YY1 regulated transcription-based stratification of gastric tumors and identification of potential therapeutic candidates.

Authors:  Divya Bhaskar Rao; Ponmathi Panneerpandian; Karthik Balakrishnan; Kumaresan Ganesan
Journal:  J Cell Commun Signal       Date:  2021-02-23       Impact factor: 5.782

8.  Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.

Authors:  S Glaysher; F G Gabriel; P Johnson; M Polak; L A Knight; K Parker; M Poole; A Narayanan; I A Cree
Journal:  Br J Cancer       Date:  2010-08-10       Impact factor: 7.640

9.  YY1-MIR372-SQSTM1 regulatory axis in autophagy.

Authors:  Lifeng Feng; Yanning Ma; Jie Sun; Qi Shen; Leiming Liu; Haiqi Lu; Faliang Wang; Yongfang Yue; Jiaqiu Li; Shenjie Zhang; Xiaoying Lin; Jue Chu; Weidong Han; Xian Wang; Hongchuan Jin
Journal:  Autophagy       Date:  2014-06-11       Impact factor: 16.016

10.  Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure.

Authors:  Yiping Huang; Dafna Kesselman; Darya Kizub; Rafael Guerrero-Preston; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2013-01-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.